AOD-9604 vs Cagrilintide
Both AOD-9604 and Cagrilintide are used for weight-loss. Here's how their evidence, dosing, and regulatory status actually compare.
AOD-9604
Evidence C+Anti-Obesity Drug 9604
A modified fragment of human growth hormone (hGH 176-191) that stimulates fat breakdown without the growth-promoting or diabetogenic effects of full HGH.
View full AOD-9604 profile →Cagrilintide
Evidence ACagrilintide (long-acting amylin analog)
A once-weekly amylin analog that reduces appetite via the area postrema. Combined with semaglutide ('CagriSema') it has produced ~22% weight loss in trial data.
View full Cagrilintide profile →Side-by-Side
| Attribute | AOD-9604 | Cagrilintide |
|---|---|---|
| Evidence Grade | C+ | A |
| FDA Status | Not FDA-approved — Category 1 (compounding allowed) | Not FDA-approved — combined with semaglutide as CagriSema; Phase 3 in progress |
| Typical Dose | 250–500 mcg daily (subcutaneous) | Trial range: 0.16–4.5 mg weekly (subcutaneous) |
| Clinics Indexed | 134 | 8 |
| Categories | weight-loss, fat-loss | weight-loss, metabolic |
Key reported benefits — AOD-9604
- ✓Fat metabolism
- ✓No HGH side effects
- ✓Cartilage repair potential
Key reported benefits — Cagrilintide
- ✓Amylin pathway weight loss
- ✓Synergy with GLP-1
- ✓Lower-dose tolerability
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.